See you there! Richard Biggs, 20, an evolutionary biology major at the University of Colorado Boulder gets his first dose of the Moderna vaccine from Dr. Laird Wolfe. Biggs is one of the first group of students in a new study to determine if the vaccine can prevent COVID-19 infection and transmission in the student population. CU Boulder students will join 12,000 other college students in the country. Glenn Asakawa/University of Colorado
Insider talked Tuesday with CEO Stephane Bancel, who highlighted five vaccine programs to watch. A caretaker helps Joost van der Westhuizen up a ramp on August 28, 2014. The South African rugby player died of ALS in 2017.
If you re new to this newsletter, sign up here. Comments, tips? Email me at lramsey@insider.com or tweet @lydiaramsey125. Let s get to it. Johnson & Johnson s coronavirus vaccine is delivered as a single shot, while both Pfizer and Moderna s require two jabs. Thiago Prudêncio/SOPA Images/LightRocket via Getty Images
Coronavirus vaccines are facing their biggest safety scare to date.
A small number of people immunized with Johnson & Johnson s or AstraZeneca s shot developed serious blood clots. Two technicians set up a patient for an MRI scan. BSIP/Universal Images Group/ Getty Images
Starting January 1, hospitals were supposed to publish prices they negotiate with insurers.
The world s largest vaccine business has been on the sidelines of the pandemic response.
GSK is facing an exodus of US vaccine scientists, with several dozen leaving in the past year.
Former GSK employees expressed frustration with the company s bureaucracy and pandemic response.
On a mild day in December 2016, GlaxoSmithKline executives snipped an orange ribbon, ushering in what they hoped would be a new chapter for the pharmaceutical giant.
GSK had just helped the world respond to the viral scares of H1N1 and Ebola, and its leaders envisioned growing their swanky vaccine-research center in suburban Rockville, Maryland, into a biopreparedness powerhouse, equipped with the research talent and manufacturing might to stop pandemics in their tracks.
CHRIS JACKSON/POOL/AFP via Getty Images
Pfizer released new data from a study indicating lasting benefits for its COVID-19 vaccine.
The company said the two-dose vaccine was 91% effective at preventing symptomatic cases of COVID-19.
Data from study volunteers in South Africa suggests the shot also repels concerning variants.
Updated results from Pfizer s late-stage study of its coronavirus vaccine indicate that the two-dose shot s overwhelming protection is holding up six months after the second dose.
The study has tallied 927 symptomatic cases of COVID-19 among the more than 46,000 trial volunteers. People who got placebo shots accounted for 850 of those cases, compared with 77 illnesses among those who received the vaccine, which was developed by Pfizer and BioNTech. That translates to 91.3% efficacy, the companies said in a statement Thursday.